Evidence map›Paper›PMID 35777762›Full record

ArticleThe European respiratory journal2022

Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally.

Tiziana Masini, Avinash Kanchar, Fuad Mirzayev, Kerri Viney, Askar Yedilbayev, Matteo Zignol, Dennis Falzon

Abstract readLetterComment
In one paragraph

Article in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Screening and treatment practices for tuberculosis infection in Nordic, Baltic and Central European countries and Ukraine in 2023.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Tiziana MasiniGlobal Tuberculosis Programme, World Health Organization, Geneva, Switzerland tmasini@who.int.
Avinash KancharGlobal Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
Fuad MirzayevGlobal Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
Kerri VineyGlobal Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
Askar YedilbayevWorld Health Organization, Regional Office for Europe, Copenhagen, Denmark.
Matteo ZignolGlobal Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
Dennis FalzonGlobal Tuberculosis Programme, World Health Organization, Geneva, Switzerland.

Funding

World Health Organization 001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

TuberculosisEuropeHumansIsoniazidRifampinIsoniazidRifampinrifapentine

Identifiers

PMID35777762
PMCPMC9403394

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.